Abstract：
BACKGROUND: Autoimmune encephalitis (AE) poses significant challenges in clinical management, requiring effective monitoring tools for therapeutic success and relapse detection. This study aims to assess the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) as compared to the modified Rankin scale (mRS) in evaluating AE patients and to determine the real-world adoption of the CASE score.
METHODS: A retrospective cohort study was conducted on 20 AE patients, assessing clinical data including symptomatology, diagnostic findings, and therapeutic regimens. Furthermore, we performed a systematic review on the test performance criteria and the real-world use of the CASE score.
RESULTS: The CASE score showed a higher sensitivity in detecting clinical changes compared to the mRS, with a significant correlation between the two scales throughout the disease course (r = 0.85, p < 0.01). A systematic review of 150 articles revealed widespread adoption of the CASE score, especially in Asian populations, demonstrating high reliability and internal consistency.
CONCLUSIONS: Despite limitations such as retrospective design and small sample size, our findings underscore the CASE score\'s utility in both clinical practice and research settings. The CASE score emerges as a valuable tool for monitoring AE patients, offering improved sensitivity over existing scales like the mRS. Further validation studies in diverse populations are warranted to establish its broader applicability and inform future therapeutic interventions.
METHODS: A retrospective cohort study was conducted on 20 AE patients, assessing clinical data including symptomatology, diagnostic findings, and therapeutic regimens. Furthermore, we performed a systematic review on the test performance criteria and the real-world use of the CASE score.
RESULTS: The CASE score showed a higher sensitivity in detecting clinical changes compared to the mRS, with a significant correlation between the two scales throughout the disease course (r = 0.85, p < 0.01). A systematic review of 150 articles revealed widespread adoption of the CASE score, especially in Asian populations, demonstrating high reliability and internal consistency.
CONCLUSIONS: Despite limitations such as retrospective design and small sample size, our findings underscore the CASE score\'s utility in both clinical practice and research settings. The CASE score emerges as a valuable tool for monitoring AE patients, offering improved sensitivity over existing scales like the mRS. Further validation studies in diverse populations are warranted to establish its broader applicability and inform future therapeutic interventions.
摘要：
背景：自身免疫性脑炎（AE）在临床管理中提出了重大挑战，需要有效的监测工具治疗成功和复发检测。本研究旨在评估自身免疫性脑炎（CASE）的临床评估量表与改良的Rankin量表（mRS）在评估AE患者中的应用，并确定CASE评分的实际采用情况。
方法：对20例AE患者进行了回顾性队列研究，评估临床数据，包括症状学，诊断结果，和治疗方案。此外，我们对测试性能标准和CASE评分的实际应用进行了系统评价.
结果：与mRS相比，CASE评分在检测临床变化方面显示出更高的灵敏度，在整个病程中，两个量表之间具有显着相关性（r=0.85，p<0.01）。对150篇文章的系统回顾显示，CASE评分得到了广泛的采用，尤其是在亚洲人群中，展示高可靠性和内部一致性。
结论：尽管有回顾性设计和小样本量等限制，我们的发现强调了CASE评分在临床实践和研究环境中的实用性.CASE评分成为监测AE患者的有价值的工具，提供比现有量表更高的灵敏度，如MRS。需要在不同人群中进行进一步的验证研究，以建立其更广泛的适用性，并为未来的治疗干预提供信息。
方法：对20例AE患者进行了回顾性队列研究，评估临床数据，包括症状学，诊断结果，和治疗方案。此外，我们对测试性能标准和CASE评分的实际应用进行了系统评价.
结果：与mRS相比，CASE评分在检测临床变化方面显示出更高的灵敏度，在整个病程中，两个量表之间具有显着相关性（r=0.85，p<0.01）。对150篇文章的系统回顾显示，CASE评分得到了广泛的采用，尤其是在亚洲人群中，展示高可靠性和内部一致性。
结论：尽管有回顾性设计和小样本量等限制，我们的发现强调了CASE评分在临床实践和研究环境中的实用性.CASE评分成为监测AE患者的有价值的工具，提供比现有量表更高的灵敏度，如MRS。需要在不同人群中进行进一步的验证研究，以建立其更广泛的适用性，并为未来的治疗干预提供信息。
